Cargando…

Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells

Pancreatic cancer (PC) frequency and incidence have grown rapidly in recent years. One of the most serious problems with PC is the existence of asymptotic manifestations, which frequently delays early detection, and until the diagnosis is established, tumor cells progress to the metastatic stage. An...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahmy, Usama A., Badr-Eldin, Shaimaa M., Aldawsari, Hibah M., Alhakamy, Nabil A., Ahmed, Osama A. A., Radwan, Mohamed F., Eid, Basma G., Sayed, Shaban R. M., El Sherbiny, Gamal A., Abualsunun, Walaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225738/
https://www.ncbi.nlm.nih.gov/pubmed/35708464
http://dx.doi.org/10.1080/10717544.2022.2072544
_version_ 1784733687162601472
author Fahmy, Usama A.
Badr-Eldin, Shaimaa M.
Aldawsari, Hibah M.
Alhakamy, Nabil A.
Ahmed, Osama A. A.
Radwan, Mohamed F.
Eid, Basma G.
Sayed, Shaban R. M.
El Sherbiny, Gamal A.
Abualsunun, Walaa
author_facet Fahmy, Usama A.
Badr-Eldin, Shaimaa M.
Aldawsari, Hibah M.
Alhakamy, Nabil A.
Ahmed, Osama A. A.
Radwan, Mohamed F.
Eid, Basma G.
Sayed, Shaban R. M.
El Sherbiny, Gamal A.
Abualsunun, Walaa
author_sort Fahmy, Usama A.
collection PubMed
description Pancreatic cancer (PC) frequency and incidence have grown rapidly in recent years. One of the most serious problems with PC is the existence of asymptotic manifestations, which frequently delays early detection, and until the diagnosis is established, tumor cells progress to the metastatic stage. Another significant concern with PC is the scarcity of well-defined pharmacotherapeutic drugs. The aim of this study was to develop an efficient nanocarrier system to augment the efficacy of raloxifene (RLX) against PC cells. As a result, the current investigation was carried out in order to give an effective treatment method, in which an optimum RLX loaded phospholipid-based vesicles with melittin (PL-MEL) was chosen using experimental design software, with particle size, zeta potential and entrapment efficiency % as dependent variables. Furthermore, anticancer activity against PANC1 cells was assessed. The optimized nanovesicle parameters were 172.5 nm for the measured size, zeta potential of –0.69 mV, and entrapment efficiency of 76.91% that were in good agreement with the expected ones. RLX-raw, plain formula, and optimized RLX-PL-MEL showed IC(50) concentrations of 26.07 ± 0.98, 9.166 ± 0.34, and 1.24 ± 0.05 µg/mL, respectively. Furthermore, cell cycle analysis revealed that the nanovesicle was most effective in the G2-M phase, whereas Bax, and Bcl-2 estimates revealed that optimized RLX formula had the highest apoptotic activity among treatments investigated. However, as compared to RLX alone or plain formula alone, the optimized formula demonstrated higher expression of TNFα and Bax while a significant reduction of Bcl-2 and NF-κB expression was observed. mitochondrial membrane potential (MMP) analysis confirmed the apoptosis as well as the anticancer effect of the optimized formula. Thus, the present study results showed an improvement in the anti-PC effects of the RLX with phospholipid conjugated melittin, making it a novel treatment approach against PC.
format Online
Article
Text
id pubmed-9225738
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-92257382022-06-24 Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells Fahmy, Usama A. Badr-Eldin, Shaimaa M. Aldawsari, Hibah M. Alhakamy, Nabil A. Ahmed, Osama A. A. Radwan, Mohamed F. Eid, Basma G. Sayed, Shaban R. M. El Sherbiny, Gamal A. Abualsunun, Walaa Drug Deliv Research Article Pancreatic cancer (PC) frequency and incidence have grown rapidly in recent years. One of the most serious problems with PC is the existence of asymptotic manifestations, which frequently delays early detection, and until the diagnosis is established, tumor cells progress to the metastatic stage. Another significant concern with PC is the scarcity of well-defined pharmacotherapeutic drugs. The aim of this study was to develop an efficient nanocarrier system to augment the efficacy of raloxifene (RLX) against PC cells. As a result, the current investigation was carried out in order to give an effective treatment method, in which an optimum RLX loaded phospholipid-based vesicles with melittin (PL-MEL) was chosen using experimental design software, with particle size, zeta potential and entrapment efficiency % as dependent variables. Furthermore, anticancer activity against PANC1 cells was assessed. The optimized nanovesicle parameters were 172.5 nm for the measured size, zeta potential of –0.69 mV, and entrapment efficiency of 76.91% that were in good agreement with the expected ones. RLX-raw, plain formula, and optimized RLX-PL-MEL showed IC(50) concentrations of 26.07 ± 0.98, 9.166 ± 0.34, and 1.24 ± 0.05 µg/mL, respectively. Furthermore, cell cycle analysis revealed that the nanovesicle was most effective in the G2-M phase, whereas Bax, and Bcl-2 estimates revealed that optimized RLX formula had the highest apoptotic activity among treatments investigated. However, as compared to RLX alone or plain formula alone, the optimized formula demonstrated higher expression of TNFα and Bax while a significant reduction of Bcl-2 and NF-κB expression was observed. mitochondrial membrane potential (MMP) analysis confirmed the apoptosis as well as the anticancer effect of the optimized formula. Thus, the present study results showed an improvement in the anti-PC effects of the RLX with phospholipid conjugated melittin, making it a novel treatment approach against PC. Taylor & Francis 2022-06-16 /pmc/articles/PMC9225738/ /pubmed/35708464 http://dx.doi.org/10.1080/10717544.2022.2072544 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fahmy, Usama A.
Badr-Eldin, Shaimaa M.
Aldawsari, Hibah M.
Alhakamy, Nabil A.
Ahmed, Osama A. A.
Radwan, Mohamed F.
Eid, Basma G.
Sayed, Shaban R. M.
El Sherbiny, Gamal A.
Abualsunun, Walaa
Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
title Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
title_full Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
title_fullStr Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
title_full_unstemmed Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
title_short Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
title_sort potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225738/
https://www.ncbi.nlm.nih.gov/pubmed/35708464
http://dx.doi.org/10.1080/10717544.2022.2072544
work_keys_str_mv AT fahmyusamaa potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT badreldinshaimaam potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT aldawsarihibahm potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT alhakamynabila potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT ahmedosamaaa potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT radwanmohamedf potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT eidbasmag potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT sayedshabanrm potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT elsherbinygamala potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells
AT abualsununwalaa potentialityofraloxifeneloadedmelittinfunctionalizedlipidicnanovesiclesagainstpancreaticcancercells